If you are already infected with HPV the risk of getting precancerous lesions/cancer may increase between 30% and 44.6% after HPV vaccination according to Merck’s own briefing document submitted to the FDA in 2006 [click here to read]. The Merck sponsored clinical study 13 exposed 156 people to Gardasil and 137 to a placebo who tested positive for one of the strains of HPV contained in the vaccine. The results showed 31 of the 156 people exposed to Gardasil developed cervical cancer as opposed to only 19 in the placebo group. Since study 13 there have been at least 278 reports of cervical cancer post-vaccination.
Read more ...Author Archive
HPV vaccination linked to cervical cancer in those already infected
Written by Sadaka Associates
Tuesday, 27 July 2010 20:54
No Comments
Tuesday, 27 July 2010 20:54
No Comments
Jury finds Fosamax caused dead jaw
Written by Sadaka Associates
Monday, 26 July 2010 23:43
No Comments
Monday, 26 July 2010 23:43
No Comments
The second trial over the drug Fosamax resulted in a verdict of $8 million dollars for Shirely Boles. Mrs. Boles, 71, sued Merck for jaw damage (dead jaw) resulting from her use of the osteoporosis drug Fosamax for 9 years.
Merck’s Fosamax (drug: Alendronate) is used to treat two bone disorders, osteoporosis in postmenopausal women and Paget’s disease. Osteoporosis causes a decrease in bone mass volume and reduction in bone strength leading to fracture of spine, wrist and hip. In Paget’s disease, healthy bone is deteriorated to poor quality bone resulting in many bone disorders. Fosamax was the first of a class of drugs called bisphosphonates which gave women an alternative to traditional treatments for osteoporosis (estrogen (female sex hormone) and calcitonin).
Read more ...
Despite risk of heart attack and stroke, Avandia stays on the market
Written by Sadaka Associates
Monday, 26 July 2010 23:40
No Comments
Monday, 26 July 2010 23:40
No Comments
The FDA voted to keep drug maker GSK’s flagship product Avandia (Rosiglitazone) can stay on the market with tougher warnings. Questions regarding the safety of GlaxoSmithKline’s blockbuster drug started after an article published in the New England Journal of Medicine showed Avandia increased the risk of heart attack.
Read more ...